Health care professionals and consumers must have access to high-quality, easy-to-use
drug information. However, some of the information provided by Canadian pharmacies is not …

To measure the quality and usefulness of patient information leaflets distributed in Canadian
pharmacies, we compared the information contained in 3 leaflets distributed in Canada for …

Informing healthcare providers of changes and updates in information about
pharmaceuticals during the post-marketing period is essential to assuring continued safe …

In 2001, we published a letter criticizing the poor quality of drug information available to the
Canadian public, 1 using as an example cisapride, a drug that had been withdrawn from the …

Abstract Purpose 'Dear Doctor'letters alert the prescribing community of drug labeling
changes that contain new contraindications, warnings, adverse reactions, and precautions …

Objective To quantify the impact of the first three label changes and 'Dear Doctor'letters as
sole interventions, sent to prescribers and pharmacists, on the prescribing and dispensing of …

Aims To assess the volume of cisapride prescribed in New Zealand to children age 0-17
years and establish whether safety announcements on cisapride had an effect on …

Objectives The Food and Drug Administration and pharmaceutical manufacturers use “Dear
doctor” letters to alert physicians about drug safety. To determine how such warnings may …

BACKGROUND: Inadequate access to useful scientifically accurate patient information is a
major cause of the inappropriate use of drugs resulting in serious personal injury and …

ContextCisapride, a gastrointestinal tract promotility agent, can cause life-threatening
cardiac arrhythmias in patients susceptible either because of concurrent use of medications …